BGM 0504
Alternative Names: BGM-0504Latest Information Update: 11 Dec 2024
Price :
$50 *
At a glance
- Originator BrightGene Bio-medical technology
- Class Antihyperglycaemics; Obesity therapies; Peptides
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Obesity; Type 2 diabetes mellitus
Most Recent Events
- 01 Dec 2024 Phase-III clinical trials in Type 2 diabetes mellitus in China (SC)(NCT06716203)
- 28 Oct 2024 Phase-III clinical trials in Obesity in China (SC) (NCT06704581)
- 21 Oct 2024 BrightGene Bio-Medical Technology initiates enrolment in a phase I trial for Obesity in USA (NCT06714955, BGM0504-P1-001-US)